A Study for HSK39775 in Participants With Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

243

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

February 1, 2028

Study Completion Date

September 1, 2028

Conditions

Advanced Solid Tumors

Interventions

DRUG

HSK39775 Monotherapy

HSK39775 will be administered orally once daily

Trial Locations (1)

RECRUITING

Fundan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Xizang Haisco Pharmaceutical Co., Ltd

INDUSTRY